SCHEMBL3836717

SCHEMBL3836717

COC(COc1ccc(C(N)=O)cc1)OC

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 17/20 0.61
PARP2 Q9UGN5 3/20 0.56
PARP4 Q9UKK3 2/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
PARP1 P09874 1/20 0.56
PARP15 Q460N3 5/20 0.50
ALDH1A1 P00352 1/20 0.50
KMT2A Q03164 1/20 0.50
PARP14 Q460N5 1/20 0.50
PARP16 Q8N5Y8 1/20 0.50
PARP11 Q9NR21 1/20 0.50
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
MAPT P10636 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
MAOB P27338 1/20 0.47
DPP4 P27487 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31752958 0.83 PARP10 (0.67) PARP10PARP2PARP4CA1CA2
SCHEMBL6305761 0.83 MAPT (0.66) CA1CA2ALDH1A1KMT2ALMNA
SCHEMBL17341985 0.82 PARP10 (0.65) PARP10PARP2PARP4CA1CA2
Hydrochloric Acid SCHEMBL29245573 0.81 PARP10 (0.62) PARP10PARP2PARP4CA1CA2
SCHEMBL30151821 0.81 PARP10 (0.62) PARP10PARP2PARP4CA1CA2
SCHEMBL10609453 0.81 PARP10 (0.62) PARP10PARP2PARP4CA1CA2
SCHEMBL9448521 0.80 POLB (0.63) PARP10PARP2PARP4CA1CA2
SCHEMBL6524478 0.80 PARP10 (0.53) PARP10PARP2PARP4CA1CA2
SCHEMBL20665416 0.79 PARP10 (0.61) PARP10PARP2PARP4CA1CA2
SCHEMBL30151899 0.79 PARP10 (0.61) PARP10PARP2PARP4CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828207-B1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-28 EP disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed
EP-1828207-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2007-09-05 EP disclosed
WO-2006066174-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R PARP10 2659/4885PARP2 4808/4885PARP4 4653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.